Clinical and Echocardiographic Characteristics and Cardiovascular Outcomes According to Diabetes Status in Patients with Heart Failure and Preserved Ejection Fraction: A Report from the I-Preserve Trial (Irbesartan in Heart Failure with Preserved Ejection Fraction)

Circulation

Volumn 135, Issue 8, 2017, Pages 724-735

  Kristensen, Søren L ^a,b   Mogensen, Ulrik M ^a,b   Jhund, Pardeep S ^a   Petrie, Mark C ^a   Preiss, David ^c   Win, Sithu ^d   Køber, Lars ^b   McKelvie, Robert S ^e   Zile, Michael R ^f   Anand, Inder S ^g   Komajda, Michel ^h   Gottdiener, John S ⁱ   Carson, Peter E ^j   McMurray, John J V ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b Rigshospitalet   (Denmark)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d MAYO CLINIC   (United States)

^e UNIVERSITY OF WESTERN ONTARIO   (Canada)

^f MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^g UNIVERSITY OF MINNESOTA   (United States)

^h SORBONNE UNIVERSITÉ   (France)

ⁱ UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

^j GEORGETOWN UNIVERSITY   (United States)

more..

Author keywords

diabetes mellitus; echocardiography; heart failure

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; IRBESARTAN; POTASSIUM; BIPHENYL DERIVATIVE; BRAIN NATRIURETIC PEPTIDE; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76); TETRAZOLE DERIVATIVE;

ADVERSE OUTCOME; AGED; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CHRONIC KIDNEY FAILURE; CLINICAL OUTCOME; COMORBIDITY; COUGHING; DIABETES MELLITUS; DOPPLER ECHOCARDIOGRAPHY; DRUG WITHDRAWAL; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE MASS; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; CARDIOVASCULAR DISEASES; COMPLICATION; CONTROLLED STUDY; DIABETES MELLITUS, TYPE 2; DIAGNOSTIC IMAGING; HEART FAILURE; HEART STROKE VOLUME; HEART VENTRICLE; INCIDENCE; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

AGED; BIPHENYL COMPOUNDS; BODY MASS INDEX; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; ECHOCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HEART VENTRICLES; HOSPITALIZATION; HUMANS; INCIDENCE; MALE; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROPORTIONAL HAZARDS MODELS; STROKE VOLUME; TETRAZOLES; TREATMENT OUTCOME;

EID: 85009382030     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.116.024593     Document Type: Article

References (22)

1. Aguilar D, Deswal A, Ramasubbu K, Mann DL, Bozkurt B, Comparison of patients with heart failure and preserved left ventricular ejection fraction among those with versus without diabetes mellitus. Am J Cardiol 2010 105 373 377. doi: 10.1016/j.amjcard.2009.09.041.
2. MacDonald MR, Petrie MC, Varyani F, Ostergren J, Michelson EL, Young JB, Solomon SD, Granger CB, Swedberg K, Yusuf S, Pfeffer MA, McMurray JJ, CHARM Investigators Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J 2008 29 1377 1385. doi: 10.1093/eurheartj/ehn153.
3. Seferović PM, Paulus WJ, Clinical diabetic cardiomyopathy: a two-faced disease with restrictive and dilated phenotypes. Eur Heart J 2015 36 1718 1727, 1727a. doi: 10.1093/eurheartj/ehv134.
4. McGuire DK, Van de Werf F, Armstrong PW, Standl E, Koglin J, Green JB, Bethel MA, Cornel JH, Lopes RD, Halvorsen S, Ambrosio G, Buse JB, Josse RG, Lachin JM, Pencina MJ, Garg J, Lokhnygina Y, Holman RR, Peterson ED, Trial Evaluating Cardiovascular Outcomes With Sitagliptin Study Group Association between sitagliptin use and heart failure hospitalization and related outcomes in type 2 diabetes mellitus: secondary analysis of a randomized clinical trial. JAMA Cardiol 2016 1 126 135. doi: 10.1001/jamacardio.2016.0103.
5. Zannad F, Cannon CP, Cushman WC, Bakris GL, Menon V, Perez AT, Fleck PR, Mehta CR, Kupfer S, Wilson C, Lam H, White WB, EXAMINE Investigators Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet 2015 385 2067 2076. doi: 10.1016/S0140-6736(14)62225-X.
6. Scirica BM, Braunwald E, Raz I, Cavender MA, Morrow DA, Jarolim P, Udell JA, Mosenzon O, Im K, Umez-Eronini AA, Pollack PS, Hirshberg B, Frederich R, Lewis BS, McGuire DK, Davidson J, Steg PG, Bhatt DL, SAVOR-TIMI 53 Steering Committee and Investigators Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation 2014 130 1579 1588. doi: 10.1161/CIRCULATIONAHA.114.010389.
7. Fitchett D, Zinman B, Wanner C, Lachin JM, Hantel S, Salsali A, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE, EMPA-REG OUTCOME® Trial Investigators Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial. Eur Heart J 2016 37 1526 1534. doi: 10.1093/eurheartj/ehv728.
8. Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Køber LV, Lawson FC, Ping L, Wei X, Lewis EF, Maggioni AP, McMurray JJ, Probstfield JL, Riddle MC, Solomon SD, Tardif JC, ELIXA Investigators Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 2015 373 2247 2257. doi: 10.1056/NEJMoa1509225.
9. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB, LEADER Steering Committee; LEADER Trial Investigators Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016 375 311 322. doi: 10.1056/NEJMoa1603827.
10. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, Woo V, Hansen O, Holst AG, Pettersson J, Vilsbøll T, SUSTAIN-6 Investigators Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016 375 1834 1844. doi: 10.1056/NEJMoa1607141.
11. Margulies KB, Hernandez AF, Redfield MM, Givertz MM, Oliveira GH, Cole R, Mann DL, Whellan DJ, Kiernan MS, Felker GM, McNulty SE, Anstrom KJ, Shah MR, Braunwald E, Cappola TP, NHLBI Heart Failure Clinical Research Network Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial. JAMA 2016 316 500 508. doi: 10.1001/jama.2016.10260.
12. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE, EMPA-REG OUTCOME Investigators Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015 373 2117 2128. doi: 10.1056/NEJMoa1504720.
13. Zile MR, Gottdiener JS, Hetzel SJ, McMurray JJ, Komajda M, McKelvie R, Baicu CF, Massie BM, Carson PE, I-PRESERVE Investigators Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction. Circulation 2011 124 2491 2501. doi: 10.1161/CIRCULATIONAHA.110.011031.
14. Carson P, Massie BM, McKelvie R, McMurray J, Komajda M, Zile M, Ptaszynska A, Frangin G, I-PRESERVE Investigators The Irbesartan in Heart Failure With Preserved Systolic Function (I-PRESERVE) trial: rationale and design. J Card Fail 2005 11 576 585. doi: 10.1016/j.cardfail.2005.06.432.
15. Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, Anderson S, Donovan M, Iverson E, Staiger C, Ptaszynska A, I-PRESERVE Investigators Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008 359 2456 2467. doi: 10.1056/NEJMoa0805450.
16. Komajda M, Carson PE, Hetzel S, McKelvie R, McMurray J, Ptaszynska A, Zile MR, Demets D, Massie BM, Factors associated with outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-PRESERVE). Circ Heart Fail 2011 4 27 35. doi: 10.1161/CIRCHEARTFAILURE.109.932996.
17. Fine JP, Gray RJ, A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999 94 496 509. doi: 10.1080/01621459.1999.10474144.
18. Nagueh SF, Smiseth OA, Appleton CP, Byrd BF 3rd, Dokainish H, Edvardsen T, Flachskampf FA, Gillebert TC, Klein AL, Lancellotti P, Marino P, Oh JK, Popescu BA, Waggoner AD, Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2016 29 277 314. doi: 10.1016/j.echo.2016.01.011.
19. Lindman BR, Dávila-Román VG, Mann DL, McNulty S, Semigran MJ, Lewis GD, de las Fuentes L, Joseph SM, Vader J, Hernandez AF, Redfield MM, Cardiovascular phenotype in HFpEF patients with or without diabetes: a RELAX trial ancillary study. J Am Coll Cardiol 2014 64 541 549. doi: 10.1016/j.jacc.2014.05.030.
20. Mohammed SF, Borlaug BA, Roger VL, Mirzoyev SA, Rodeheffer RJ, Chirinos JA, Redfield MM, Comorbidity and ventricular and vascular structure and function in heart failure with preserved ejection fraction: a community-based study. Circ Heart Fail 2012 5 710 719. doi: 10.1161/CIRCHEARTFAILURE.112.968594.
21. Henkel DM, Redfield MM, Weston SA, Gerber Y, Roger VL, Death in heart failure: a community perspective. Circ Heart Fail 2008 1 91 97. doi: 10.1161/CIRCHEARTFAILURE.107.743146.
22. Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, Clausell N, Desai AS, Diaz R, Fleg JL, Gordeev I, Harty B, Heitner JF, Kenwood CT, Lewis EF, O'Meara E, Probstfield JL, Shaburishvili T, Shah SJ, Solomon SD, Sweitzer NK, Yang S, McKinlay SM, TOPCAT Investigators Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 2014 370 1383 1392. doi: 10.1056/NEJMoa1313731.